Overview

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long. In addition the disease-related symptoms will be evaluated. The safety of the drugs will be determined based upon evaluation of the side effects
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Capecitabine
Docetaxel
Gemcitabine